Search

everythinglearnresearchcommunity

for

Search:↓

The April 2016 JEADV issue covered various dermatology topics, including psoriasis, psoriatic arthritis, mTOR inhibitors, autoimmune diseases, photodynamic therapy, viral DNA in skin diseases, chronic hand eczema, and female hair loss.

The book details skin conditions in older adults, their link to mental health, cancer treatment importance, hair loss remedies, and managing autoimmune and itchy skin.

Herpes gestationis is linked to certain antigens, atopic eczema affects T cell populations and may be eased by breastfeeding, higher doses of anti-androgen treatment can improve androgenic alopecia, topical minoxidil increases hair thickness, long-term methotrexate therapy can cause liver fibrosis in psoriasis patients, and Lichen Sclerosus et Atrophicus patients aren't at higher risk for autoimmune disorders.

Alopecia areata is an autoimmune disease where T cells attack hair follicles.

Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.

Avacopan is generally safe, with some minor side effects like nausea and fatigue.

Alopecia areata is an autoimmune disorder causing hair loss, linked to specific hair follicle antigens and genetic factors.

Vaccines are generally safe, but rare autoimmune reactions can occur, often influenced by genetics.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

Lupus can cause different skin problems, and treatments like quitting smoking and using certain creams or medicines can help.

Tissue environment greatly affects the unique epigenetic makeup of regulatory T cells, which could impact autoimmune disease treatment.

JAK inhibitors show promise in treating skin conditions like eczema, hair loss, and vitiligo but need more safety research.

The 11th AICPE Congress in Rimini was a major event in European aesthetic plastic surgery.

Hair loss from Telogen Effluvium usually gets better within 6 months after addressing the cause.

Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.

Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.

Type I interferons play a key role in the development of various skin diseases.

Aggressive immunosuppressive treatment improved a woman's severe heart condition linked to autoimmune disease.

Graves' disease can cause hair loss in children and should be considered when treating pediatric alopecia areata.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Vitiligo affects overall health and self-esteem, needing more research and awareness.

The document concludes that mouse models are crucial for studying hair biology and that all mutant mice may have hair growth abnormalities that require detailed analysis to identify.

Premature graying of hair may suggest health issues and currently lacks effective treatments.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Reproductive factors can increase hypertension risk and affect cardiovascular health.

Recognizing and treating skin symptoms in essential thrombocythemia is crucial for patient quality of life.

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.